

# Lisa M Kaminskas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9489581/publications.pdf>

Version: 2024-02-01

80  
papers

4,191  
citations

101543

36  
h-index

114465

63  
g-index

80  
all docs

80  
docs citations

80  
times ranked

5084  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | From sewer to saviour “targeting the lymphatic system to promote drug exposure and activity. Nature Reviews Drug Discovery, 2015, 14, 781-803.   | 46.4 | 479       |
| 2  | Dendrimer pharmacokinetics: the effect of size, structure and surface characteristics on ADME properties. Nanomedicine, 2011, 6, 1063-1084.  | 3.3  | 166       |
| 3  | The Impact of Molecular Weight and PEG Chain Length on the Systemic Pharmacokinetics of PEGylated Poly-L-lysine Dendrimers. Molecular Pharmaceutics, 2008, 5, 449-463.   | 4.6  | 165       |
| 4  | Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. Journal of Controlled Release, 2014, 183, 18-26.   | 9.9  | 158       |
| 5  | A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine: Nanotechnology, Biology, and Medicine, 2012, 8, 103-111.   | 3.3  | 152       |
| 6  | Cationic Poly-L-lysine Dendrimers: Pharmacokinetics, Biodistribution, and Evidence for Metabolism and Bioresorption after Intravenous Administration to Rats. Molecular Pharmaceutics, 2006, 3, 614-627.   | 4.6  | 149       |
| 7  | PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats. Journal of Controlled Release, 2009, 140, 108-116.  | 9.9  | 130       |
| 8  | Pharmacokinetics and Tumor Disposition of PEGylated, Methotrexate Conjugated Poly-L-lysine Dendrimers. Molecular Pharmaceutics, 2009, 6, 1190-1204.  | 4.6  | 130       |
| 9  | Association of Chemotherapeutic Drugs with Dendrimer Nanocarriers: An Assessment of the Merits of Covalent Conjugation Compared to Noncovalent Encapsulation. Molecular Pharmaceutics, 2012, 9, 355-373.   | 4.6  | 125       |
| 10 | Characterisation and tumour targeting of PEGylated polylysine dendrimers bearing doxorubicin via a pH labile linker. Journal of Controlled Release, 2011, 152, 241-248.  | 9.9  | 121       |
| 11 | The effect of amino acid excipients on morphology and solid-state properties of multi-component spray-dried formulations for pulmonary delivery of biomacromolecules. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 83, 234-243. | 4.3  | 115       |
| 12 | New developments in dry powder pulmonary vaccine delivery. Trends in Biotechnology, 2011, 29, 191-198.   | 9.3  | 109       |
| 13 | Targeting the lymphatics using dendritic polymers (dendrimers). Advanced Drug Delivery Reviews, 2011, 63, 890-900.   | 13.7 | 108       |
| 14 | Nano-chemotherapeutics: Maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers. Journal of Controlled Release, 2014, 193, 241-256.  | 9.9  | 107       |
| 15 | Pulmonary Administration of PEGylated Polylysine Dendrimers: Absorption from the Lung versus Retention within the Lung Is Highly Size-Dependent. Molecular Pharmaceutics, 2013, 10, 2986-2995.   | 4.6  | 93        |
| 16 | Influence of Size and Shape on the Biodistribution of Nanoparticles Prepared by Polymerization-Induced Self-Assembly. Biomacromolecules, 2017, 18, 3963-3970.  | 5.4  | 87        |
| 17 | Aldehyde-sequestering drugs: tools for studying protein damage by lipid peroxidation products. Toxicology, 2002, 181-182, 229-236.   | 4.2  | 78        |
| 18 | PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. Journal of Controlled Release, 2013, 172, 128-136.                                     | 9.9  | 74        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | PEGylation of interferon $\hat{\pm}2$ improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases. <i>Journal of Controlled Release</i> , 2013, 168, 200-208.                         | 9.9 | 70        |
| 20 | Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance. <i>Journal of Pharmaceutical Sciences</i> , 2011, 100, 5069-5077.  | 3.3 | 67        |
| 21 | Disposition and safety of inhaled biodegradable nanomedicines: Opportunities and challenges. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1703-1724.  | 3.3 | 67        |
| 22 | Polymer-drug conjugates as inhalable drug delivery systems: A review. <i>Current Opinion in Colloid and Interface Science</i> , 2017, 31, 18-29.  | 7.4 | 66        |
| 23 | Strong Protein Adduct Trapping Accompanies Abolition of Acrolein-Mediated Hepatotoxicity by Hydralazine in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 1003-1010.   | 2.5 | 64        |
| 24 | Doxorubicin-Conjugated PEGylated Dendrimers Show Similar Tumoricidal Activity but Lower Systemic Toxicity When Compared to PEGylated Liposome and Solution Formulations in Mouse and Rat Tumor Models. <i>Molecular Pharmaceutics</i> , 2012, 9, 422-432.                           | 4.6 | 63        |
| 25 | Capping Methotrexate $\hat{\pm}$ -Carboxyl Groups Enhances Systemic Exposure and Retains the Cytotoxicity of Drug Conjugated PEGylated Polylysine Dendrimers. <i>Molecular Pharmaceutics</i> , 2011, 8, 338-349.  | 4.6 | 61        |
| 26 | Protein Adduct-Trapping by Hydrazinophthalazine Drugs: Mechanisms of Cytoprotection Against Acrolein-Mediated Toxicity. <i>Molecular Pharmacology</i> , 2004, 65, 655-664.  | 2.3 | 55        |
| 27 | Investigating the interactions of amino acid components on a mannitol-based spray-dried powder formulation for pulmonary delivery: A design of experiment approach. <i>International Journal of Pharmaceutics</i> , 2011, 421, 220-229.   | 5.2 | 51        |
| 28 | Methotrexate-Conjugated PEGylated Dendrimers Show Differential Patterns of Deposition and Activity in Tumor-Burdened Lymph Nodes after Intravenous and Subcutaneous Administration in Rats. <i>Molecular Pharmaceutics</i> , 2015, 12, 432-443.                                     | 4.6 | 51        |
| 29 | Impact of Surface Derivatization of Poly-lysine Dendrimers with Anionic Arylsulfonate or Succinate Groups on Intravenous Pharmacokinetics and Disposition. <i>Molecular Pharmaceutics</i> , 2007, 4, 949-961.   | 4.6 | 50        |
| 30 | The Lymphatic System Plays a Major Role in the Intravenous and Subcutaneous Pharmacokinetics of Trastuzumab in Rats. <i>Molecular Pharmaceutics</i> , 2014, 11, 496-504.  | 4.6 | 49        |
| 31 | Reactivity of hydrazinophthalazine drugs with the lipid peroxidation products acrolein and crotonaldehyde. <i>Organic and Biomolecular Chemistry</i> , 2004, 2, 2578.   | 2.8 | 47        |
| 32 | Spray-Dried Influenza Antigen with Trehalose and Leucine Produces an Aerosolizable Powder Vaccine Formulation that Induces Strong Systemic and Mucosal Immunity after Pulmonary Administration. <i>Journal of Aerosol Medicine and Pulmonary Drug Delivery</i> , 2015, 28, 361-371. | 1.4 | 42        |
| 33 | A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 125, 1-12.                            | 4.3 | 42        |
| 34 | Prediction and Optimization of Pharmacokinetic and Toxicity Properties of the Ligand. <i>Methods in Molecular Biology</i> , 2018, 1762, 271-284.  | 0.9 | 42        |
| 35 | Reducing Dendrimer Generation and PEG Chain Length Increases Drug Release and Promotes Anticancer Activity of PEGylated Polylysine Dendrimers Conjugated with Doxorubicin via a Cathepsin-Cleavable Peptide Linker. <i>Molecular Pharmaceutics</i> , 2018, 15, 4568-4576.           | 4.6 | 41        |
| 36 | Microfluidic preparation of drug-loaded PEGylated liposomes, and the impact of liposome size on tumour retention and penetration. <i>Journal of Liposome Research</i> , 2019, 29, 1-9.  | 3.3 | 39        |

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 37 | Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible?. Drug Development and Industrial Pharmacy, 2019, 45, 882-894.   | 2.0  | 37        |
| 38 | PEGylation Does Not Significantly Change the Initial Intravenous or Subcutaneous Pharmacokinetics or Lymphatic Exposure of Trastuzumab in Rats but Increases Plasma Clearance after Subcutaneous Administration. Molecular Pharmaceutics, 2015, 12, 794-809.                       | 4.6  | 34        |
| 39 | dendPoint: a web resource for dendrimer pharmacokinetics investigation and prediction. Scientific Reports, 2019, 9, 15465.   | 3.3  | 32        |
| 40 | Hyaluronic Acid Molecular Weight Determines Lung Clearance and Biodistribution after Instillation. Molecular Pharmaceutics, 2016, 13, 1904-1914.   | 4.6  | 30        |
| 41 | Differences in Lysine Adduction by Acrolein and Methyl Vinyl Ketone: Implications for Cytotoxicity in Cultured Hepatocytes. Chemical Research in Toxicology, 2005, 18, 1627-1633.  | 3.3  | 28        |
| 42 | Effect of increased surface hydrophobicity via drug conjugation on the clearance of inhaled PEGylated polylysine dendrimers. European Journal of Pharmaceutics and Biopharmaceutics, 2017, 119, 408-418.   | 4.3  | 28        |
| 43 | Local inflammation alters the lung disposition of a drug loaded pegylated liposome after pulmonary dosing to rats. Journal of Controlled Release, 2019, 307, 32-43.  | 9.9  | 26        |
| 44 | Conjugation of 10 kDa Linear PEG onto Trastuzumab Fab Is Sufficient to Significantly Enhance Lymphatic Exposure while Preserving in Vitro Biological Activity. Molecular Pharmaceutics, 2016, 13, 1229-1241.   | 4.6  | 25        |
| 45 | Suggested Procedures for the Reproducible Synthesis of Poly(D,L-lactide-co-glycolide) Nanoparticles Using the Emulsification Solvent Diffusion Platform. Current Nanoscience, 2018, 14, 448-453.   | 1.2  | 25        |
| 46 | Optimal PEGylation can Improve the Exposure of Interferon in the Lungs Following Pulmonary Administration. Journal of Pharmaceutical Sciences, 2015, 104, 1421-1430.   | 3.3  | 24        |
| 47 | Aerosol Pirfenidone Pharmacokinetics after Inhaled Delivery in Sheep: a Viable Approach to Treating Idiopathic Pulmonary Fibrosis. Pharmaceutical Research, 2020, 37, 3.   | 3.5  | 23        |
| 48 | A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep. Pharmaceutical Research, 2016, 33, 510-525.  | 3.5  | 22        |
| 49 | Lymphatic transport and lymph node targeting of methotrexate-conjugated PEGylated dendrimers are enhanced by reducing the length of the drug linker or masking interactions with the injection site. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 2485-2494.     | 3.3  | 22        |
| 50 | The impact of size and charge on the pulmonary pharmacokinetics and immunological response of the lungs to PLGA nanoparticles after intratracheal administration to rats. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 30, 102291.                                   | 3.3  | 22        |
| 51 | Designing a Multicomponent Spray-Dried Formulation Platform for Pulmonary Delivery of Biomacromolecules: The Effect of Polymers on the Formation of an Amorphous Matrix for Glassy State Stabilization of Biomacromolecules. Drying Technology, 2013, 31, 1451-1458.               | 3.1  | 20        |
| 52 | Designing a multi-component spray-dried formulation platform for pulmonary delivery of biopharmaceuticals: The use of polyol, disaccharide, polysaccharide and synthetic polymer to modify solid-state properties for glassy stabilisation. Powder Technology, 2016, 287, 248-255. | 4.2  | 20        |
| 53 | Lymph-directed immunotherapy – Harnessing endogenous lymphatic distribution pathways for enhanced therapeutic outcomes in cancer. Advanced Drug Delivery Reviews, 2020, 160, 115-135.  | 13.7 | 18        |
| 54 | Molecular weight (hydrodynamic volume) dictates the systemic pharmacokinetics and tumour disposition of PolyPEG star polymers. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 2099-2108.   | 3.3  | 17        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | The Pharmacokinetics and Biodistribution of a 64 kDa PolyPEG Star Polymer After Subcutaneous and Pulmonary Administration to Rats. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 293-300.   | 3.3 | 17        |
| 56 | Recent advances in nano/microparticle-based oral vaccines. <i>Journal of Pharmaceutical Investigation</i> , 2021, 51, 425-438.   | 5.3 | 17        |
| 57 | Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery. <i>Journal of Controlled Release</i> , 2018, 272, 17-28.                                    | 9.9 | 16        |
| 58 | The contribution of the metabolite p -hydroxyamphetamine to the central actions of p -methoxyamphetamine. <i>Psychopharmacology</i> , 2002, 160, 155-160.  | 3.1 | 15        |
| 59 | Michael addition of acrolein to lysinyl and N-terminal residues of a model peptide: targets for cytoprotective hydrazino drugs. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 1155-1164.  | 1.5 | 15        |
| 60 | An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration. <i>Biomacromolecules</i> , 2017, 18, 2866-2875.   | 5.4 | 15        |
| 61 | Drug formulation and nanomedicine approaches to targeting lymphatic cancer metastases. <i>Nanomedicine</i> , 2019, 14, 1605-1621.  | 3.3 | 15        |
| 62 | Chaperone Heat Shock Protein 90 Mobilization and Hydralazine Cytoprotection against Acrolein-Induced Carbonyl Stress. <i>Molecular Pharmacology</i> , 2012, 82, 876-886.   | 2.3 | 14        |
| 63 | Doxorubicin Conjugation and Drug Linker Chemistry Alter the Intravenous and Pulmonary Pharmacokinetics of a PEGylated Generation 4 Polylysine Dendrimer in Rats. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 2509-2513.                                   | 3.3 | 13        |
| 64 | Linker chemistry dictates the delivery of a phototoxic organometallic rhenium( <i>&lt;sc&gt;i&lt;/i&gt;</i> ) complex to human cervical cancer cells from core crosslinked star polymer nanoparticles. <i>Journal of Materials Chemistry B</i> , 2018, 6, 7805-7810. | 5.8 | 9         |
| 65 | A 30 kDa polyethylene glycol-enfuvirtide complex enhances the exposure of enfuvirtide in lymphatic viral reservoirs in rats. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 137, 218-226.   | 4.3 | 9         |
| 66 | Trisulfide-Bearing PEG Brush Polymers Donate Hydrogen Sulfide and Ameliorate Cellular Oxidative Stress. <i>Biomacromolecules</i> , 2020, 21, 5292-5305.  | 5.4 | 8         |
| 67 | The Impact of Polymer Size and Cleavability on the Intravenous Pharmacokinetics of PEG-Based Hyperbranched Polymers in Rats. <i>Nanomaterials</i> , 2020, 10, 2452.  | 4.1 | 8         |
| 68 | Nanosized Drug Delivery Vectors and the Reticuloendothelial System. <i>Fundamental Biomedical Technologies</i> , 2011, , 155-178.  | 0.2 | 7         |
| 69 | Poly(HPMA-co-NIPAM) copolymer as an alternative to polyethylene glycol-based pharmacokinetic modulation of therapeutic proteins. <i>International Journal of Pharmaceutics</i> , 2021, 608, 121075.  | 5.2 | 7         |
| 70 | Development of a hyperbranched polymer-based methotrexate nanomedicine for rheumatoid arthritis. <i>Acta Biomaterialia</i> , 2022, 142, 298-307.   | 8.3 | 7         |
| 71 | PEGylated Interferon Displays Differences in Plasma Clearance and Bioavailability Between Male and Female Mice and Between Female Immunocompetent C57Bl/6J and Athymic Nude Mice. <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 1848-1855.                  | 3.3 | 6         |
| 72 | Depolymerization of hyaluronan using PEGylated human recombinant hyaluronidase promotes nanoparticle tumor penetration. <i>Nanomedicine</i> , 2021, 16, 275-292.   | 3.3 | 5         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | The Applications of 3D Printing in Pulmonary Drug Delivery and Treatment of Respiratory Disorders. <i>Current Pharmaceutical Design</i> , 2019, 24, 5072-5080.   | 1.9 | 5         |
| 74 | Cetuximab Exhibits Sex Differences in Lymphatic Exposure after Intravenous Administration in Rats in the Absence of Differences in Plasma Exposure. <i>Pharmaceutical Research</i> , 2020, 37, 224.                                  | 3.5 | 4         |
| 75 | The pharmacokinetics of PEGylated liposomal doxorubicin are not significantly affected by sex in rats or humans, but may be affected by immune dysfunction. <i>Journal of Controlled Release</i> , 2021, 337, 71-80.                 | 9.9 | 4         |
| 76 | Practical Lessons in Murine Thoracic Lymph Duct Cannulations: Observations in Female and Male Mice Across Four Different Strains That Impact on "Cannulatability". <i>Journal of Pharmaceutical Sciences</i> , 2015, 104, 1207-1209. | 3.3 | 3         |
| 77 | Nitroxide-functional PEGylated nanostars arrest cellular oxidative stress and exhibit preferential accumulation in co-cultured breast cancer cells. <i>Journal of Materials Chemistry B</i> , 2021, 9, 7805-7820.                    | 5.8 | 3         |
| 78 | Monocytes Do Not Contribute to Sex Differences Seen in the Pharmacokinetics of Pegylated Liposomal Doxorubicin. <i>Journal of Pharmaceutical Sciences</i> , 2021, 110, 3099-3101.  | 3.3 | 2         |
| 79 | Liposomes are Poorly Absorbed via Lung Lymph After Inhaled Administration in Sheep. <i>Frontiers in Pharmacology</i> , 0, 13, .  | 3.5 | 1         |
| 80 | Dendrimers for Biomedical Applications. <i>Frontiers in Nanobiomedical Research</i> , 2014, , 279-328.   | 0.1 | 0         |